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Theaimofthisresearchwas topurifyandcharacterize themodeofactionofenterocinS37,abacteriocinproducedby Enterococcus
faecalis S37, a strain recently isolated from the chicken feces. Enterocin S37 has a molecular weight comprised between 4 and
5kDa. It remained active after 1h at 80oC and at pH values ranging from 4.0 to 9.0. Furthermore, cell-free supernatant of
Enterococcus faecalis S37 and puriﬁed enterocin S37 were active against Gram-positive bacteria including Listeria monocytogenes
EGDe, L. innocua F, Enterococcus faecalis JH2-2, and Lactobacillus brevis F145. The puriﬁcation of enterocin S37 was performed
by ammonium sulfate precipitation followed up by hydrophobic-interaction chromatography procedures. Treatment of enterocin
S37 with proteinase K, α-chymotrypsin, and papain conﬁrmed its proteinaceous nature, while its treatment with lysozyme and
lipase resulted in no alteration of activity. Enterocin S37 is hydrophobic, anti-Listeria and likely acting by depletion of intracellular
K+ ions upon action on KATP channels. This study contributed to gain more insights into the mode of action of enterocins.
1.Introduction
Bacteriocins are ribosomally synthesized antimicrobial pep-
tides produced by bacteria that deserve considerable interest
for their use as natural and nontoxic food preservatives
as well as for their potential use in human and veterinary
applications, and in the animal production ﬁeld [1]. In 1976
Tagg et al. deﬁned bacteriocins as proteinaceous compounds
that kill closely related bacteria but it is now recognized
that bacteriocins can also have activity across genera (broad
spectrum) [2–4]. The antimicrobial sensitivity of a target
strain to any given bacteriocin may depend on the ecological
conditions under which it is grown as variations in salt
concentration, pH, the presence of membrane disrupting
molecules, or inducing cultures, and a large number of other
environmental parameters can have a signiﬁcant impact
[5, 6]. The classiﬁcation of Gram-positive bacteriocins is
rendered diﬃcult because of their heterogeneity and thus,
as the number of Gram-positive bacteriocins identiﬁed has
continued to increase, classiﬁcation schemes have had to
continuously evolve [1].
Klaenhammer [8] suggested four classes of bacteriocins
including class I or lantibiotics, which are small membrane-
active peptides (<5kDa) containing the unusual amino
acids lanthionine or β-methyl lanthionine (hence the name
lantibiotics) and dehydrated residues. Nisin is the most
characterized of the class I bacteriocins. Class II is deﬁned
as small heat-stable nonlanthionine containing membrane
active peptides characterized by the presence of a Gly-Gly
processing site in the bacteriocins precursor, the presence of
amphiphilic helices with varying amounts of hydrophobicity
and moderate to high-heat stability. These were further2 Journal of Environmental and Public Health
Table 1: Antimicrobial activities of partially puriﬁed enterocin S37.
Strains Reference Source and reference Enterocin S37
Enterococcus faecalis S37 [7] −
Enterococcus faecalis JH2-2 Laboratory collection +
Listeria monocytogenes EGDe 107776 CIP (Paris, France) +++
Listeria innocua F Laboratory collection ++
Lactobacillus bulgaricus 340 Laboratory collection −
Lb. brevis F1.114 Laboratory collection ++
Lb. brevis F145 Laboratory collection +
Pseudomonas sp. 131 Laboratory collection −
Escherichia coli 76.24 CIP (Paris, France) −
Salmonella montevideo Laboratory collection −
Sal. enterica serotype enteritidis 81.3 CIP (Paris, France) −
Staphylococcus epidermidis 68.21 CIP (Paris, France) −
Campylobacter jejuni 11168 NCTC (London, UK) −
Bacillus cereus 78.3 CIP (Paris, France) −
Leuconostoc mesenteroides subsp. mesenteroides 20240 DSM (Braunschweig, Germany) −
Streptococcus haemolyticus Laboratory collection −
–: Absence of inhibition,+: Diameter of inhibition zone was less than 3mm,++: Diameter of inhibition zone was comprised between 3 and 6mm,+++:
Diameter of inhibition zone was higher than 6mm.
subdivided into three subgroups named subclass IIa, which
are Listeria active peptides and YGNGV box in the N-
terminal [9]; subclass IIb: poration complexes consisting of
t w op r o t e i n a c e o u sp e p t i d e sf o ra c t i v i t y[ 10] and subclass IIc,
which contains thiol activated peptides requiring reduced
cysteyl residues for activity [8]. Class III is large heat labile
proteins, often with enzymatic activity and ﬁnally class IV,
which is composed of complex proteins. However, recent
classiﬁcation reported only three major classes [11].
Many Enterococcus strains from various ecosystems were
characterized as antagonists of broad range of foodborne
pathogens [12, 13]. The bacteriocins produced by enterococ-
calstrainsdisplayedheterogeneousstructuresanddiﬀerences
in their mode of action [14]. Most of bacteriocin Producers
enterococcal strains were isolated not only from diﬀerent
types of food, but also from broilers [2, 4] and animal
secretions [15]. As reported in the literature, some of these
bacteriocins exhibited high activities against broad spectrum
of bacteria including Gram-positive bacteria, like Staphy-
lococcus and Streptococcus and Gram-negative bacteria like
Campylobacter orSalmonella,strainsofmedicalinterest[2,4,
16]. The ability to produce such a biocompound may play a
role in providing an ecological advantage on nonbacteriocin
producer strains. Previously, we have isolated a strain of
E. faecalis from chicken drop [7] which appeared to be a
bacteriocin producer. In this work, we have undertaken the
puriﬁcation and characterization of the mode of action of
this peptide named enterocin S37.
2.MaterialsandMethods
2.1. Bacteriocin Producer Strain. E. faecalis S37 was isolated
from poultry feces collected in a French farm located in
Ancenis (West of France) [7]. E. faecalis S37 was identiﬁed
by sequencing whole 16S rRNA gene [7]. E. faecalis S37
showed in ﬁrst instance an antagonism directed against
strains belonging to Listeria and Campylobacter species [7].
2.2. Antimicrobial Activity. The antibacterial activity of ente-
rocin S37 was assessed against the Gram-negative and Gram-
positive bacteria listed in Table 1. The cell-free supernatant
(CFS) and partially puriﬁed enterocin S37, by ammonium
sulfate precipitation and two successive reversed phase-
high performance liquid chromatography (RP-HPLC) steps,
were used in order to assess the antagonism toward the
target strains listed in Table 1. E. faecalis S37, E. faecalis
JH2-2, Lactobacillus brevis F1.114, Lb. bulgaricus 340, Lb.
brevis F145, Pseudomonas sp. 131, Escherichia coli CIP 76.24,
Salmonella montevideo, Sal. enterica serotype enteritidis CIP
81.3, Staphylococcus epidermidis CIP 68.21, Bacillus cereus
CIP 78.3,and Leuconostoc mesenteroides subsp. mesenteroides
DSM20240weregrownonBrainHeartInfusionbroth(BHI)
medium (AES, Bruz France), whilst L. monocytogenes EGDe
and L. innocua F were grown on Elliker medium (AES).
Campylobacter jejuni NCTC 11168 was grown in Brucella
medium (AES).
The antibacterial activity was measured by the well
known agar diﬀusion test [12]. For this purpose, 100μL
from overnight culture of targeted strains was added to
20ml of Elliker or BHI soft agar medium already containing
0.8% (w/v) of agar (Biokar diagnostics, Beauvais, France).
W e l l sw e r ep e r f o r m e di ns o l i da g a ra n d5 0 μlo fe a c h
sample tested was poured into the wells. The Petri dishes
were left at room temperature, in sterile conditions, for
1h before incubation for 18h at adequate temperature
according to the target strain to be tested. After this periodJournal of Environmental and Public Health 3
of incubation, the antibacterial activity was detected by
observing the inhibition zones around the well containing
the CFS. It should be noted that supernatant was obtained
bycentrifugingat15000gduring30minat4◦C,anovernight
culture of E. faecalis grown at 37
◦C for 18 to 24h, on de Man
Rogosa Sharpe (MRS) medium [17] (AES). The CFS was
neutralized by addition of 1N NaOH and ﬁltered through
0.2μm membrane (Sartorius, Goettingen, Germany).
Arbitrary Unit (AU) was calculated as described by
Batdorj et al. [12]. Serial two fold dilution of samples
was performed with phosphate buﬀer (25mM K2HPO4,
25mM KH2PO4, pH 7) ﬁltered through 0.2μmm e m b r a n e
(Sartorius). These samples were tested by agar diﬀusion test
on L. monocytogenes EGDe strain, as described previously.
One arbitrary unit was deﬁned as the reciprocal of the lowest
dilution that did not show growth of the target strain.
2.3. Bacteriocin Puriﬁcation. The CFS neutralized and ﬁl-
tered (400ml) was precipitated with ammonium sulfate
to 80% saturated solution. Three distinct fractions were
recovered and were resuspended in 40ml of phosphate
buﬀer (25mM K2HPO4,2 5m MK H 2PO4, pH 7); the active
one was applied onto RP-HPLC column (ATOLL 15 MP3;
250mm × 10mm Interchim, Montluc ¸on, France)previously
equilibrated with solvent A (0.05%, v/v, triﬂuoroacetic acid
[TFA]). Elution was performed by using a gradient from
0% solvent B (0.045%, v/v, TFA, 80% acetonitrile) to
100% solvent B in 45min. The ﬂow rate was adjusted to
3ml.min−1 and the absorbance was recorded at 220 and
280nm. Fractions of 10ml were collected and tested for their
antibacterial activity. The acetonitrile was removed from
the active fractions by Speed-Vac concentrator (SC110A,
Savant) and pH was adjusted to 6.8 using phosphate buﬀer
(50mM; pH 7). The active fractions were pooled and the
puriﬁcation of the bacteriocin was continued by RP-HPLC
on a Waters Alliance apparatus with Millennium software
(Millford, MA, USA). Concentrated bacteriocin (80μl) was
injected into an analytical C18 column (Symmetry 300; 5
μm; Spherical 300 ˚ A; 150 × 4.6mm, Waters, Guyancourt,
France) equilibrated in 0% solvent C (0.045% TFA in H2O)
and 50% solvent D (80% acetonitrile, 20% H2O, 0.05%
TFA). The elution was performed with a linear gradient
from 30% to 100% solvent D in 30min. The ﬂow rate was
adjusted to 0.8mlmin−1. The eluted peaks were detected
by spectrophotometry measuring the absorbance between
210 and 300nm with a photo diode array detector (PDA
996; Waters) and collected manually. The fractions were then
concentrated in a Speed-Vac concentrator.
2.4.EﬀectofEnzymes,pHandHeatTreatmentonAntibacterial
Activity of Bacteriocin. The eﬀect of α-chymotrypsin (1mg ·
ml
−1), papain (1mg · ml
−1), proteinase K (0.5mg/ml−1),
lysozyme (2mg·ml
−1), and lipase (1mg·ml
−1)( a lle n z ym e s
were from Sigma-Aldrich, Germany) on the antibacterial
activity of enterocin S37 was checked by the agar diﬀusion
assay as described by Batdorj et al. [12]. CFS was treated
with the aforementioned enzymes for 1h at 37
◦C. The pH
stability was studied as described by Line et al. [2]. Thus,
samples (CFS) of 10 ml were adjusted to pH values ranging
f r o m3t o1 0w i t h1 NH C lo r1 NN a O H .T h eo b t a i n e d
f r a c t i o n sw e r ei n c u b a t e df o r2ha t3 7
◦C. After this period of
incubation, the antibacterial activity of each treated sample
was determined by the agar well diﬀusion assay [12]. The





◦C for 15min. After cooling in ice, each sample was
tested for its antagonism by agar well diﬀusion assay [12].
2.5. Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Elec-
trophoresis (PAGE). In order to determine the apparent
molecular mass of enterocin S37, the SDS-PAGE gel was cut
into two parts. The part of the gel containing the molecular
markers and the samples were stained by silver nitrate
coloration method [18], and the remaining part, containing
only samples, was extensively washed with regularly replaced
sterileMilliQwater.Secondpartofthegelwasusedfordirect
detection of antimicrobial activity by overlaying with soft
agar (0.8%) seeded with indicator strain L. monocytogenes
EGDe and incubated overnight at 37
◦C.
2.6. Development of Bacteriocin-Resistant Variants to Ente-
rocinS37. ResistantvariantstoenterocinS37weredeveloped
by stepwise culture of strain of L. monocytogenes EGDe
at 30
◦C in tryptic soy broth (Biokar diagnostics) supple-
mented with 0.6% (w/v) yeast extract (Organotechnie SA, La
Courneuve, France) and called TSYE broth (TSYEB). Ente-
rocin S37 was added at 2- 4- 6- 8- and 10-fold the minimal
inhibitory concentration (MIC). The MIC was determined
for L. monocytogenes EGDe according to Naghmouchi et al.
[19] using microplate reader ELx808 (BioTek Instruments,
Bad Friedrichshall, Germany). The stability of the resistant
variants was checked over 50 generations. After growth of 50
generations in TSYEB at 30
◦C, the strain was inoculated in
the TSYEB containing enterocin S37 at 10-fold MIC.
2.7.EﬀectofK+ ChannelModulators. L.monocytogenesEGDe
and its bacteriocin-resistant variant were grown at 30
◦Cf o r
24h in TSYEB in the presence of enterocin S37 at 5μg ·
ml
−1and K+ channel modulators such as pinacidil (Pi) at
10μg · ml
−1, cromakalim (Cro) at 10μg · ml
−1 and glipizide
(Gli) at 10μg · ml
−1 Combination of enterocin S37 with
each of K+ channel modulator was also realized in similar
conditions. All these K+ channel modulators were obtained
from Sigma-Aldrich (Germany). Growth was monitored by
measuring the optical density at 595nm (OD595) of 250μl
of freshly inoculated medium placed into microplate wells
[19].
The inhibitory activity (IA) of enterocin S37 in presence
or absence of each K+ channel modulator was calculated as
described by Naghmouchi et al. [19]. Clearly, a percentage
of IA = 100 – 100 (OD595(x)/OD595(i)) (during exponential
growth). The value (x) was the culture containing inhibitor
and (i) was the uninhibited control culture. Data were
expressed as the percent change in IA obtained with the
enterocin S37/K+ channel modulator.4 Journal of Environmental and Public Health
3. Results
3.1. Spectrum of Activity of Enterocin S37. CFS of E. faecalis
S37 displayed activities against E. faecalis JH2-2, Lb. brevis
F1.114, Lb. brevis F145, L. monocytogenes EGDe, and L.
innocua F. However, none antibacterial activity was detected
against the remaining strains listed in Table 1. Surprisingly,
the anti-Campylobacter activity previously observed [7]w a s
not recovered in this study arguing on instability trait
(Table 1). Furthermore, the activity observed against strains
of Enterococcus genus is interesting in order to generate novel
knowledgeonimmunityproteinsandcross-resistancewithin
this genus.
3.2. Eﬀects of Enzymatic and Physicochemical Treatments
on Enterocin S37 Activity. CFS of E. faecalis S37 displayed
activity against the target strains E. faecalis JH2-2, Lb. brevis
F1.114, Lb. brevis F145, L. monocytogenes EGDe and L.
innocua F even after treatments with lipase (1mg·ml
−1)a n d
lysozyme (2mg·ml
−1). The antibacterial activity observed
upon lipase and lysozyme treatments was similar to that
observed with the untreated supernatant used as positive
controls. However, treatment with proteolytic enzymes, such
as α-chymotrypsin, papain, and proteinase K resulted in the
loss of the bacteriocin activity (Table 2). The stability of
antibacterial activity of enterocin S37 remained intact after
heating treatments (80
◦Cf o r1ha n d9 0
◦C for 15min) and at
pH values ranging from 4 to 9 (Table 2). Attempts to reduce
putative disulﬁde bridge (s) of enterocin S37 were performed
with dithiothreitol (Sigma, Germany); the experiment was
not conclusive because of toxicity of this compound, even at
low concentrations, towards the target strains.
3.3. Puriﬁcation of Enterocin S37. The bacteriocin was puri-
ﬁed by a three-step method including ammonium sulfate
precipitation and two RP-HPLC. The ﬁrst stage consisted in
an ammonium sulfate precipitation at 80%, which allowed
concentrating the active fraction 10-fold (v/v); subsequently,
the active fraction was passed through two successive RP-
HPLC columns. Active fractions (those exhibiting antibacte-
rial activity) were eluted at 60% of elution buﬀer containing
80% acetonitrile, 20% H2O, and 0.05% TFA. The purity of
each active fraction collected after each step was checked on
SDS-PAGE (Table 3, Figure 1).
Bacteriocin appeared to have a molecular weight com-
prised between 4 and 6kDa (Figure 1(a)), and ﬁtting
thereof with the inhibition zone observed on SDS-PAGE
(Figure 1(b)). For this purpose, the electrophoresis gel
obtained after migration under nondenaturing conditions
was plated directly on Elliker soft agar (0.9%) inoculated
with L. monocytogenes EGDe with 1% volume transfer (v/v).
The other proteins bands revealed by electrophoresis were
devoid of antibacterial activity. The antimicrobial activity of
each sample, obtained during puriﬁcation process, was also
checked by agar diﬀusion test on Petri dish (Figure 1(c))
3.4. Eﬀect of K+ Channel Modulators. Both K+ channel acti-
vators (pinacidil and cromakalim) and inhibitor (glipizide)
Table 2: Eﬀect of enzymes, pH, and heat treatment on antibacterial









































◦C, 15 min ++
80
◦C, 60 min ++
90
◦C, 15 min ++
+: Antibacterial activity detected; −: Absence of antibacterial activity.
aﬀecteddiﬀerentlythegrowthofL.monocytogenesEGDeand
its bacteriocin-resistant variant to enterocin S37 obtained in
this research. As shown in Figure 2, the highest eﬀect was
attributed to the combination of enterocin S37 (5μg · ml
−1)
and pinacidil (10μg ·ml
−1). Eﬀect of the combinations of
enterocin S37 with cromakalim (10μg ·ml
−1) and glipizide
(10μg ·ml
−1) was less important on L. monocytogenes EGDe
bacteriocin-resistant variant.
4. Discussion
Enterococci are known to be widespread in nature. For
most enterococcal species, the predominant habitat is the
gastrointestinal tract of animals and humans where they
can be found in numbers as high as 108 cfu/g of feces
[20]. Enterococci were found in foods of animal origin

















Figure 1: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Tricine-SDS-PAGE). (a) Silver-stained gel. Lane 1: molecular
weights markers; lane 2: culture supernatant of E. faecalis S37; lane 3: heat and ﬁltered supernatant culture of E. faecalis S37; lane 4: active
fraction collected after ammonium sulfate precipitation; lane 5: active peak obtained after ﬁrst RP-HPLC; lane 6: active peak obtained after
second RP-HPLC. (b) The gel was overlaid with L. monocytogenes EGDe to determine the antimicrobial activity of the puriﬁed enterocin
S37; lane 7: active peak obtained after ﬁrst RP-HPLC; lane 8: active peak obtained after second RP-HPLC. (c) Agar diﬀusion test. Well
1: negative control (phosphate buﬀer); well 2: heated and ﬁltered supernatant culture of E. faecalis S37; well 3: active fraction collected
after ammonium sulfate precipitation; well 4: active peak obtained after ﬁrst RP-HPLC; well 5: active peak obtained after second RP-
HPLC.
materials[21].Additionallytothesenaturalhabitats,theyare
implicated in nosocomial infections [22].
Many enterococci were reported to produce bacteri-
ocins called enterocins, which are various, having great
diversity in their structure, and active against numerous
microorganisms,especiallyfoodbornepathogensandagainst
microorganisms of environmental and medical interests [2,
4, 14, 23]. Theppangna et al. [15] have studied a set of 139
strains of E. faecium and E. faecalis for their capabilities
to produce enterocins and they concluded that 51% of
isolates were producers of enterocins and 46% of them
were able to produce more than one enterocin. The strains
producing enterocins were carrying at least one structural
gene coding for the most known enterocins (entA, entP,
entL50AB and cylL)[ 15]. Other studies pointed out the
importance of E. faecalis as sources of enterocins [24, 25].
Taken together, these studies indicate the distribution and
importance of enterococcal strains. It should be pointed
out that most of enterocins so far studied exhibited activity
towards Gram-negative and Gram-positive bacteria [8]. We
have undertaken isolation and characterization of enterocin
named enterocin S37, which is produced by E. faecalis
recently isolated from chicken feces [7]. Enterocin S37
appeared to be interesting regarding its activities against the
food-borne pathogen L. monocytogenes EGDe and casually
against Campylobacter jejuni NCTC 11168 (Table 1). How-
ever the anti-Campylobacter activity remained unstable and
less important than that observed for other bacteriocins
recently reported in the literature [2–4]. The data gathered
from this study let us think of the possibility of enterocin
S37 to be a class IIa bacteriocin, as (i) this peptide was
anti-Listeria, (ii) has a molecular weight < 10kDa, (iii) was
sensitive to proteases, and (iv) was stable at diﬀerent pH and
high temperatures.
Results of puriﬁcation indicated that enterocin S37
was highly hydrophobic. The activity increased several
folds (from 400AU ·ml
−1 to 51,200AU ·ml
−1) during the
puriﬁcation process (Table 3), in parallel with an increase6 Journal of Environmental and Public Health
Table 3: Puriﬁcation of enterocin S37 produced by Enterococcus faecalis S37.
Puriﬁcation step Volume (ml) Protein concentration




Filtered culture supernatant 400 10,647.94 400 0.03 1
Ammonium sulfate precipitation 40 5,079.03 12,800 2.52 84
First RP-HPLC 10 56.64 51,200 903.95 30,132
Second RP-HPLC 1 32.88 51,200 1,557.17 51,906
∗Arbitrary Unit was calculated as described by Batdorj et al. [12].


































L. monocytogenes EGDe sensitive strain
L. monocytogenes EGDe variant resistant
Figure 2: Inhibitory activity of L. monocytogenes EGDe sensitive
strain and its variant resistant after exposure to enterocin S37 alone
(EntS37; 5mg · ml
−1) and K+ channel modulators alone: pinacidil
(Pi; 10μg ·ml
−1), cromakalim (Cro; 10μg ·ml
−1) and glipizide
(Gli; 10μg ·ml
−1). Values are the mean of three independent
measurements.
of speciﬁc activity, which reaches 1,557.17 AU ·μg
−1. This
phenomenonwaslargelydescribedpreviouslyastheresultof
removing inhibitory compounds [26–28]. The spectrum of
partiallypuriﬁedenterocinS37wasthesametothatobserved
with CFS, but with stronger activities (data not shown).
For the ﬁrst time, the eﬀect of K+ channel modulators on
enterocin activity was revealed in this research. To this aim,
we have utilized two K+ channel activators (cromakalim
and pinacidil) and one K+ channel blocker (glipizide).
Cromakalim was shown to act on ATP-sensitive potassium
channels and caused membrane hyper polarization, pulls
their membrane potential away from the threshold [29]. In
the pharmacology sector, the use of cromakalim to treating
hypertension was reported [29]. Pinacidil is a cyanoguani-
dine drug that opens ATP-sensitive potassium channels [30].
Finally, glipizide was described to aﬀect the cell by partially
blocking the K+ channels, reducing K+ conductance and
causing depolarization of the membrane, which leads to
Ca++ ions inﬂux through voltage-sensitive Ca++ channels,
causing rising of the intracellular concentrations of Ca++
ions [31, 32]. Furthermore, the impact of cromakalim
and glipizide on growth of sensitive and resistant L.
monocytogenes strains was studied and resulted to be overall
weak. Thus, the inhibition of wildtype (sensitive phenotype)
to cromakalim and glipizide was estimated to 14.29%± 1.38
and 17.14%± 4.08 while the inhibition of the mutant strain
(resistant phenotype) was evaluated to 4.46%± 3.53 and
8.93%± 1.06. Pinacidil showed high-inhibitory activity on
the wildtype (86.79%± 1.78) and interestingly not on the
mutant strain (19.64%± 4.02).
Combinations of enterocin S37 and diﬀerent K+ channel
modulators suggested an implication of enterocin S37 in a
depletion of intracellular K+ level, by an action on KATP
channels rather than Kv channels. These data are in good
agreement with those obtained formerly with nisin A, whose
antibacterial activity was connected to KATP channels with
concomitant loss of all intracellular K+ and ATP [19]. As for
enterocin AS-48 and enterocin P [33, 34], enterocin S37 is
certainly responsible of uncontrolled eﬄux of intracellular
K+ and aﬀecting sensitive cells growth. The resistant variant
was able to grow but was slightly aﬀected by the combination
of enterocin S37/K+ modulators, except for pinacidil, where
the inhibitory eﬀect has reached 49.79%± 3.36, instead of
23.84%± 7.73 and 24.11%± 7.07 when cromakalim and
glipizide were added, respectively (Figure 2).
It was also well established that many bacteriocins,
including enterocins, interact with membrane lipids leading
to the formation of pores and subsequently to the loss of
intracellular components, resulting thereof in the cell death
[35–39]. The lipid composition of membrane appeared to
playanimportantroleintheeﬃciencyofbacteriocinactivity
[9, 35, 36, 38]. Enterocin S37 alone did not aﬀect the
growth of bacteriocin-resistant variant of L. monocytogenes
EGDe. However, the combination of enterocin S37/K+ chan-
nel modulators impacted strongly the growth of resistant
variant. Otherwise, the K+ channel modulators enhanced
the inhibitory activity of enterocin S37 on sensitive strain
of L. monocytogenes EGDe, with values reaching, 92.86%±
5.90 and 94.29%± 4.55 when enterocin S37 was combined
with glipizide and pinacidil, respectively. Combination of
cromakalim and enterocin S37 resulted in 84.29%± 2.5
inhibition of the growth of sensitive strain; this data is equal
to that obtained with enterocin S37 alone 84.21%± 5.87
(Figure 2). However, in the case of resistant strain, when
enterocin S37 was combined to pinacidil, a high-inhibitory
activity(49.79%±3.36)wasobservedascomparedtocombi-
nations of cromakalim + enterocin S37 (23.84%± 7.73) and
enterocin S37 + glipizide (24.11%± 7.07) (Figure 2).
The mode of action of enterocin S37 could be triggered
by potential interaction with cell membrane. The determi-
nation of aminoacid sequence of enterocin S37 is under
consideration.Journal of Environmental and Public Health 7
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